A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.

Item
http://www.wikidata.org/entity/Q33378668
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Inhibitors of tubulin assembly identified through screening a compound library.Synthesis and antiproliferative activities of ottelione a analoguesBiological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitorComprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investmentA phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasisMicrotubule dynamics as a target in oncology.Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitroTime to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents.Tubulin inhibitors: a patent review.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.
P2860

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.

Item
http://www.wikidata.org/entity/Q33378668
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
A phase I study of ABT-751, an ...... ic patients with solid tumors.
@ast
A phase I study of ABT-751, an ...... ic patients with solid tumors.
@en
type
label
A phase I study of ABT-751, an ...... ic patients with solid tumors.
@ast
A phase I study of ABT-751, an ...... ic patients with solid tumors.
@en
prefLabel
A phase I study of ABT-751, an ...... ic patients with solid tumors.
@ast
A phase I study of ABT-751, an ...... ic patients with solid tumors.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
A phase I study of ABT-751, an ...... ic patients with solid tumors.
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-07-4097
P407
P433
P478
P50
P577
P698